 | • レポートコード：MRC2-11QY12582 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は悪性リンパ腫のグローバル市場について調査・分析したレポートです。種類別（リンパ節、骨髄、脾臓、血液、その他の臓器）市場規模、用途別（製薬会社、病院、学術研究所）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別悪性リンパ腫の競争状況、市場シェア ・世界の悪性リンパ腫市場：種類別市場規模 2015年-2020年（リンパ節、骨髄、脾臓、血液、その他の臓器） ・世界の悪性リンパ腫市場：種類別市場規模予測 2021年-2026年（リンパ節、骨髄、脾臓、血液、その他の臓器） ・世界の悪性リンパ腫市場：用途別市場規模 2015年-2020年（製薬会社、病院、学術研究所） ・世界の悪性リンパ腫市場：用途別市場規模予測 2021年-2026年（製薬会社、病院、学術研究所） ・北米の悪性リンパ腫市場分析：米国、カナダ ・ヨーロッパの悪性リンパ腫市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの悪性リンパ腫市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の悪性リンパ腫市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの悪性リンパ腫市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Abbott Laboratories、Abiogen Pharma、Actelion Pharmaceuticals、Bristol-Myers Squibb ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Cancers that start anywhere in the body’s lymphatic system are called lymphomas. If they have the ability to spread, they are called malignant. The lymphatic system runs throughout our bodies and is composed of lymphoid tissue, vessels, and fluid. Lymphoid tissue contains lymph nodes, which are part of the immune system. The immune system’s job is to produce blood cells and protect against harm from invading germs.
The two main types of malignant lymphoma are Hodgkin lymphoma(also known as Hodgkin disease) and NHL. The two types spread in different ways and respond differently to treatment. When lymphomais of a slow-growing variety, it is referred to as low-grade. Aggressive, fast-growing types are called high-grade. A biopsy can also detect the difference between Hodgkin lymphomaand NHL, as well as their various sub-types. Along with imaging and blood tests, the biopsy results will help doctor determine course of treatment.
Market Analysis and Insights: Global Malignant Lymphoma Market
The global Malignant Lymphoma market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Malignant Lymphoma Scope and Market Size
Malignant Lymphoma market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Malignant Lymphoma market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Abbott Laboratories
Abiogen Pharma
Actelion Pharmaceuticals
Bristol-Myers Squibb
…
Market segment by Type, the product can be split into
Lymph Nodes
Bone Marrow
Spleen
Blood
Other Organs
Market segment by Application, split into
Pharmaceutical Companies
Hospitals
Academic And Research Institutes
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Malignant Lymphoma Revenue
1.4 Market by Type
1.4.1 Global Malignant Lymphoma Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Lymph Nodes
1.4.3 Bone Marrow
1.4.4 Spleen
1.4.5 Blood
1.4.6 Other Organs
1.5 Market by Application
1.5.1 Global Malignant Lymphoma Market Share by Application: 2020 VS 2026
1.5.2 Pharmaceutical Companies
1.5.3 Hospitals
1.5.4 Academic And Research Institutes
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Malignant Lymphoma Market Perspective (2015-2026)
2.2 Global Malignant Lymphoma Growth Trends by Regions
2.2.1 Malignant Lymphoma Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Malignant Lymphoma Historic Market Share by Regions (2015-2020)
2.2.3 Malignant Lymphoma Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Malignant Lymphoma Market Growth Strategy
2.3.6 Primary Interviews with Key Malignant Lymphoma Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Malignant Lymphoma Players by Market Size
3.1.1 Global Top Malignant Lymphoma Players by Revenue (2015-2020)
3.1.2 Global Malignant Lymphoma Revenue Market Share by Players (2015-2020)
3.1.3 Global Malignant Lymphoma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Malignant Lymphoma Market Concentration Ratio
3.2.1 Global Malignant Lymphoma Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Malignant Lymphoma Revenue in 2019
3.3 Malignant Lymphoma Key Players Head office and Area Served
3.4 Key Players Malignant Lymphoma Product Solution and Service
3.5 Date of Enter into Malignant Lymphoma Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Malignant Lymphoma Historic Market Size by Type (2015-2020)
4.2 Global Malignant Lymphoma Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Malignant Lymphoma Market Size by Application (2015-2020)
5.2 Global Malignant Lymphoma Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Malignant Lymphoma Market Size (2015-2020)
6.2 Malignant Lymphoma Key Players in North America (2019-2020)
6.3 North America Malignant Lymphoma Market Size by Type (2015-2020)
6.4 North America Malignant Lymphoma Market Size by Application (2015-2020)
7 Europe
7.1 Europe Malignant Lymphoma Market Size (2015-2020)
7.2 Malignant Lymphoma Key Players in Europe (2019-2020)
7.3 Europe Malignant Lymphoma Market Size by Type (2015-2020)
7.4 Europe Malignant Lymphoma Market Size by Application (2015-2020)
8 China
8.1 China Malignant Lymphoma Market Size (2015-2020)
8.2 Malignant Lymphoma Key Players in China (2019-2020)
8.3 China Malignant Lymphoma Market Size by Type (2015-2020)
8.4 China Malignant Lymphoma Market Size by Application (2015-2020)
9 Japan
9.1 Japan Malignant Lymphoma Market Size (2015-2020)
9.2 Malignant Lymphoma Key Players in Japan (2019-2020)
9.3 Japan Malignant Lymphoma Market Size by Type (2015-2020)
9.4 Japan Malignant Lymphoma Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Malignant Lymphoma Market Size (2015-2020)
10.2 Malignant Lymphoma Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Malignant Lymphoma Market Size by Type (2015-2020)
10.4 Southeast Asia Malignant Lymphoma Market Size by Application (2015-2020)
11 India
11.1 India Malignant Lymphoma Market Size (2015-2020)
11.2 Malignant Lymphoma Key Players in India (2019-2020)
11.3 India Malignant Lymphoma Market Size by Type (2015-2020)
11.4 India Malignant Lymphoma Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Malignant Lymphoma Market Size (2015-2020)
12.2 Malignant Lymphoma Key Players in Central & South America (2019-2020)
12.3 Central & South America Malignant Lymphoma Market Size by Type (2015-2020)
12.4 Central & South America Malignant Lymphoma Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Abbott Laboratories
13.1.1 Abbott Laboratories Company Details
13.1.2 Abbott Laboratories Business Overview
13.1.3 Abbott Laboratories Malignant Lymphoma Introduction
13.1.4 Abbott Laboratories Revenue in Malignant Lymphoma Business (2015-2020))
13.1.5 Abbott Laboratories Recent Development
13.2 Abiogen Pharma
13.2.1 Abiogen Pharma Company Details
13.2.2 Abiogen Pharma Business Overview
13.2.3 Abiogen Pharma Malignant Lymphoma Introduction
13.2.4 Abiogen Pharma Revenue in Malignant Lymphoma Business (2015-2020)
13.2.5 Abiogen Pharma Recent Development
13.3 Actelion Pharmaceuticals
13.3.1 Actelion Pharmaceuticals Company Details
13.3.2 Actelion Pharmaceuticals Business Overview
13.3.3 Actelion Pharmaceuticals Malignant Lymphoma Introduction
13.3.4 Actelion Pharmaceuticals Revenue in Malignant Lymphoma Business (2015-2020)
13.3.5 Actelion Pharmaceuticals Recent Development
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Details
13.4.2 Bristol-Myers Squibb Business Overview
13.4.3 Bristol-Myers Squibb Malignant Lymphoma Introduction
13.4.4 Bristol-Myers Squibb Revenue in Malignant Lymphoma Business (2015-2020)
13.4.5 Bristol-Myers Squibb Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Malignant Lymphoma Key Market Segments
Table 2. Key Players Covered: Ranking by Malignant Lymphoma Revenue
Table 3. Ranking of Global Top Malignant Lymphoma Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Malignant Lymphoma Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Lymph Nodes
Table 6. Key Players of Bone Marrow
Table 7. Key Players of Spleen
Table 8. Key Players of Blood
Table 9. Key Players of Other Organs
Table 10. Global Malignant Lymphoma Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Malignant Lymphoma Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Malignant Lymphoma Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Malignant Lymphoma Market Share by Regions (2015-2020)
Table 14. Global Malignant Lymphoma Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Malignant Lymphoma Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Malignant Lymphoma Market Growth Strategy
Table 20. Main Points Interviewed from Key Malignant Lymphoma Players
Table 21. Global Malignant Lymphoma Revenue by Players (2015-2020) (Million US$)
Table 22. Global Malignant Lymphoma Market Share by Players (2015-2020)
Table 23. Global Top Malignant Lymphoma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Lymphoma as of 2019)
Table 24. Global Malignant Lymphoma by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Malignant Lymphoma Product Solution and Service
Table 27. Date of Enter into Malignant Lymphoma Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Malignant Lymphoma Market Size by Type (2015-2020) (Million US$)
Table 30. Global Malignant Lymphoma Market Size Share by Type (2015-2020)
Table 31. Global Malignant Lymphoma Revenue Market Share by Type (2021-2026)
Table 32. Global Malignant Lymphoma Market Size Share by Application (2015-2020)
Table 33. Global Malignant Lymphoma Market Size by Application (2015-2020) (Million US$)
Table 34. Global Malignant Lymphoma Market Size Share by Application (2021-2026)
Table 35. North America Key Players Malignant Lymphoma Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Malignant Lymphoma Market Share (2019-2020)
Table 37. North America Malignant Lymphoma Market Size by Type (2015-2020) (Million US$)
Table 38. North America Malignant Lymphoma Market Share by Type (2015-2020)
Table 39. North America Malignant Lymphoma Market Size by Application (2015-2020) (Million US$)
Table 40. North America Malignant Lymphoma Market Share by Application (2015-2020)
Table 41. Europe Key Players Malignant Lymphoma Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Malignant Lymphoma Market Share (2019-2020)
Table 43. Europe Malignant Lymphoma Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Malignant Lymphoma Market Share by Type (2015-2020)
Table 45. Europe Malignant Lymphoma Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Malignant Lymphoma Market Share by Application (2015-2020)
Table 47. China Key Players Malignant Lymphoma Revenue (2019-2020) (Million US$)
Table 48. China Key Players Malignant Lymphoma Market Share (2019-2020)
Table 49. China Malignant Lymphoma Market Size by Type (2015-2020) (Million US$)
Table 50. China Malignant Lymphoma Market Share by Type (2015-2020)
Table 51. China Malignant Lymphoma Market Size by Application (2015-2020) (Million US$)
Table 52. China Malignant Lymphoma Market Share by Application (2015-2020)
Table 53. Japan Key Players Malignant Lymphoma Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Malignant Lymphoma Market Share (2019-2020)
Table 55. Japan Malignant Lymphoma Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Malignant Lymphoma Market Share by Type (2015-2020)
Table 57. Japan Malignant Lymphoma Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Malignant Lymphoma Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Malignant Lymphoma Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Malignant Lymphoma Market Share (2019-2020)
Table 61. Southeast Asia Malignant Lymphoma Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Malignant Lymphoma Market Share by Type (2015-2020)
Table 63. Southeast Asia Malignant Lymphoma Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Malignant Lymphoma Market Share by Application (2015-2020)
Table 65. India Key Players Malignant Lymphoma Revenue (2019-2020) (Million US$)
Table 66. India Key Players Malignant Lymphoma Market Share (2019-2020)
Table 67. India Malignant Lymphoma Market Size by Type (2015-2020) (Million US$)
Table 68. India Malignant Lymphoma Market Share by Type (2015-2020)
Table 69. India Malignant Lymphoma Market Size by Application (2015-2020) (Million US$)
Table 70. India Malignant Lymphoma Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Malignant Lymphoma Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Malignant Lymphoma Market Share (2019-2020)
Table 73. Central & South America Malignant Lymphoma Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Malignant Lymphoma Market Share by Type (2015-2020)
Table 75. Central & South America Malignant Lymphoma Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Malignant Lymphoma Market Share by Application (2015-2020)
Table 77. Abbott Laboratories Company Details
Table 78. Abbott Laboratories Business Overview
Table 79. Abbott Laboratories Product
Table 80. Abbott Laboratories Revenue in Malignant Lymphoma Business (2015-2020) (Million US$)
Table 81. Abbott Laboratories Recent Development
Table 82. Abiogen Pharma Company Details
Table 83. Abiogen Pharma Business Overview
Table 84. Abiogen Pharma Product
Table 85. Abiogen Pharma Revenue in Malignant Lymphoma Business (2015-2020) (Million US$)
Table 86. Abiogen Pharma Recent Development
Table 87. Actelion Pharmaceuticals Company Details
Table 88. Actelion Pharmaceuticals Business Overview
Table 89. Actelion Pharmaceuticals Product
Table 90. Actelion Pharmaceuticals Revenue in Malignant Lymphoma Business (2015-2020) (Million US$)
Table 91. Actelion Pharmaceuticals Recent Development
Table 92. Bristol-Myers Squibb Company Details
Table 93. Bristol-Myers Squibb Business Overview
Table 94. Bristol-Myers Squibb Product
Table 95. Bristol-Myers Squibb Revenue in Malignant Lymphoma Business (2015-2020) (Million US$)
Table 96. Bristol-Myers Squibb Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Malignant Lymphoma Market Share by Type: 2020 VS 2026
Figure 2. Lymph Nodes Features
Figure 3. Bone Marrow Features
Figure 4. Spleen Features
Figure 5. Blood Features
Figure 6. Other Organs Features
Figure 7. Global Malignant Lymphoma Market Share by Application: 2020 VS 2026
Figure 8. Pharmaceutical Companies Case Studies
Figure 9. Hospitals Case Studies
Figure 10. Academic And Research Institutes Case Studies
Figure 11. Malignant Lymphoma Report Years Considered
Figure 12. Global Malignant Lymphoma Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Malignant Lymphoma Market Share by Regions: 2020 VS 2026
Figure 14. Global Malignant Lymphoma Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Malignant Lymphoma Market Share by Players in 2019
Figure 17. Global Top Malignant Lymphoma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Lymphoma as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Malignant Lymphoma Revenue in 2019
Figure 19. North America Malignant Lymphoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Malignant Lymphoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Malignant Lymphoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Malignant Lymphoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Malignant Lymphoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Malignant Lymphoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Malignant Lymphoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed
悪性神経膠腫の世界市場（～2026年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…- 悪性神経膠腫治療の世界市場（～2026年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…
- 成人用悪性神経膠腫治療薬の世界市場（～2026年） Glioblastoma multiforme (GBM) is among the most difficult of tumors to treat, and despite all efforts, median overall survival remains at approximately 12 months. Malignant gliomas are included in the category of rare diseases, and the orphan drug status is granted for the drug candidates in the pip…
- 悪性神経膠腫治療薬の世界市場（～2026年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…
- 悪性中皮腫治療の世界市場（～2026年） Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium). Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is…